R Bassan, T Intermesoli, O Spinelli, E Oldani, A Rambaldi
{"title":"青年和成人Ph-ALL的现代治疗。","authors":"R Bassan, T Intermesoli, O Spinelli, E Oldani, A Rambaldi","doi":"10.1038/leusup.2012.6","DOIUrl":null,"url":null,"abstract":"<p><p>Acute lymphoblastic leukemia (ALL) in adults is currently associated with an overall survival rate of around 40% at 5 years. This is an unsatisfactory result that makes it imperative to dissect further the biology of the disease in order to identify highly specific therapeutic targets to implement selectively the cure rate. The recognition of discrete ALL subsets followed by the application of risk-oriented therapies has been a major achievement over the past 30 years. </p>","PeriodicalId":91571,"journal":{"name":"Leukemia supplements","volume":"1 Suppl 2","pages":"S5-6"},"PeriodicalIF":0.0000,"publicationDate":"2012-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1038/leusup.2012.6","citationCount":"2","resultStr":"{\"title\":\"Modern therapy of young and adult Ph-ALL.\",\"authors\":\"R Bassan, T Intermesoli, O Spinelli, E Oldani, A Rambaldi\",\"doi\":\"10.1038/leusup.2012.6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Acute lymphoblastic leukemia (ALL) in adults is currently associated with an overall survival rate of around 40% at 5 years. This is an unsatisfactory result that makes it imperative to dissect further the biology of the disease in order to identify highly specific therapeutic targets to implement selectively the cure rate. The recognition of discrete ALL subsets followed by the application of risk-oriented therapies has been a major achievement over the past 30 years. </p>\",\"PeriodicalId\":91571,\"journal\":{\"name\":\"Leukemia supplements\",\"volume\":\"1 Suppl 2\",\"pages\":\"S5-6\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2012-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1038/leusup.2012.6\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Leukemia supplements\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1038/leusup.2012.6\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2012/8/9 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Leukemia supplements","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1038/leusup.2012.6","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2012/8/9 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
Acute lymphoblastic leukemia (ALL) in adults is currently associated with an overall survival rate of around 40% at 5 years. This is an unsatisfactory result that makes it imperative to dissect further the biology of the disease in order to identify highly specific therapeutic targets to implement selectively the cure rate. The recognition of discrete ALL subsets followed by the application of risk-oriented therapies has been a major achievement over the past 30 years.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
